OBJECTIVE： To evaluate therapeutic efficacy and safety of total glucosides of paeony （TGP） capsule combined with sulfasalazine tablet versus sulfasalazine tablet in the treatment of ankylosing spondylitis （AS）， and to provide evidence-based reference for clinical use. METHODS： Retrieved from PubMed， EMBase， Medline， Cochrane library， CJFD， VIP and Wanfang database， RCTs about therapeutic efficacy （total response rate， morning stiffness duration， chest expansion， joint pain index， erythrocyte sedimentation rate， CRP， Schober trial value） and safety （diarrhea， incidence of leucopenia abnormal liver function） of TGP capsule combined with sulfasalazine tablet （trial group） vs. sulfasalazine tablet alone （control group） in the treatment of AS were collected. After data extraction of literatures met inclusion criteria and quality evaluation with Cochrane risk bias evaluation tool 5.1.0， Meta-analysis was performed by using Rev Man 5.3 statistical software. RESULTS： 9 RCTs were included， involving 593 patients. Meta-analysis showed that total response rate [OR＝3.90，95％CI（2.24，6.80）， P＜0.01]， morning stiffness duration [MD＝－5.05，95％CI（－6.96，－3.14）， P＜0.01]， chest expansion [MD＝0.26， 95％CI（0.07，0.46）， P＜0.01]， joint pain index [MD＝－1.28， 95％CI（－2.13，－0.43）， P＜0.01]， CRP [MD＝－0.78，95％CI（－1.44，－0.12）， P＝0.02] and the incidence of abnormal liver function [MD＝0.23， 95％CI（0.10，0.50）， P＜0.01] of trial group were better than those of control group. There was no statistical difference in erythrocyte sedimentation rate [MD＝－2.68，95％CI（－8.45，3.08）， P＝0.36]， Schober trial value [MD＝0.24，95％CI（－0.15，0.63）， P＝0.23]， the incidence of diarrhea [OR＝1.39，95％CI（0.62，3.12）， P＝0.43] or leucopenia [OR＝0.33，95％CI（0.06，1.79）， P＝0.20] between 2 groups. CONCLUSIONS： TGP capsule combined with sulfasalazine tablet can significantly improve total response rate， shorten morning stiffness duration， expand the degree of chest expansion， reduce joint pain index and CRP level， and decrease the occurrence of abnormal liver function.